Foghorn Therapeutics’ Strategic Shift and Financial Strength Bolster Buy Rating Amid ...
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Foghorn Therapeutics (FHTX – Research Report), with a ...